Addex Operating Margin from 2010 to 2026
| ADXN Stock | CHF 0.05 0.0006 1.13% |
Check Addex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Addex Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 222.4 K, Interest Expense of 3 K or Total Revenue of 350.6 K, as well as many indicators such as Price To Sales Ratio of 14.95, Dividend Yield of 0.0 or PTB Ratio of 0.5. Addex financial statements analysis is a perfect complement when working with Addex Therapeutics Valuation or Volatility modules.
Addex | Operating Margin |
The evolution of Operating Margin for Addex Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Addex Therapeutics compares to historical norms and industry peers.
Latest Addex Therapeutics' Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Addex Therapeutics over the last few years. It is Addex Therapeutics' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Addex Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (14.04) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Addex Operating Margin Regression Statistics
| Arithmetic Mean | (44.08) | |
| Coefficient Of Variation | (164.78) | |
| Mean Deviation | 56.58 | |
| Median | (6.47) | |
| Standard Deviation | 72.63 | |
| Sample Variance | 5,275 | |
| Range | 223 | |
| R-Value | 0.47 | |
| Mean Square Error | 4,390 | |
| R-Squared | 0.22 | |
| Significance | 0.06 | |
| Slope | 6.74 | |
| Total Sum of Squares | 84,407 |
Addex Operating Margin History
About Addex Therapeutics Financial Statements
Addex Therapeutics investors use historical fundamental indicators, such as Addex Therapeutics' Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Addex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system disorders in Switzerland. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Plan-les-Ouates, Switzerland. ADDEX N operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 17 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Addex Stock Analysis
When running Addex Therapeutics' price analysis, check to measure Addex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Addex Therapeutics is operating at the current time. Most of Addex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Addex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Addex Therapeutics' price. Additionally, you may evaluate how the addition of Addex Therapeutics to your portfolios can decrease your overall portfolio volatility.